Die Ablösung der klassischen Zytostatika durch BCL-2- und BCR-Inhibitoren geht in die nächste Runde

Andres, Martin (2018). Die Ablösung der klassischen Zytostatika durch BCL-2- und BCR-Inhibitoren geht in die nächste Runde. Leading Opinions. Hämatologie & Onkologie, 14(1), pp. 28-30. Universimed

[img] Text
LO_onko_1801_MA.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (4MB)

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Andres, Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1991-2838

Publisher:

Universimed

Language:

German

Submitter:

Pierrette Durand Lüthi

Date Deposited:

27 Feb 2019 16:10

Last Modified:

05 Dec 2022 15:25

BORIS DOI:

10.7892/boris.125170

URI:

https://boris.unibe.ch/id/eprint/125170

Actions (login required)

Edit item Edit item
Provide Feedback